These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
356 related items for PubMed ID: 16614237
1. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia. Boccia R, Malik IA, Raja V, Kahanic S, Liu R, Lillie T, Tomita D, Clowney B, Silberstein P. Oncologist; 2006 Apr; 11(4):409-17. PubMed ID: 16614237 [Abstract] [Full Text] [Related]
2. The effectiveness of darbepoetin alfa administered every 3 weeks on hematologic outcomes and quality of life in older patients with chemotherapy-induced anemia. Boccia R, Lillie T, Tomita D, Balducci L. Oncologist; 2007 May; 12(5):584-93. PubMed ID: 17522247 [Abstract] [Full Text] [Related]
3. Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia. Hernandez E, Ganly P, Charu V, Dibenedetto J, Tomita D, Lillie T, Taylor K, ARANESP 20030232 Study Group. Curr Med Res Opin; 2009 Sep; 25(9):2109-20. PubMed ID: 19601709 [Abstract] [Full Text] [Related]
4. Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Auerbach M, Silberstein PT, Webb RT, Averyanova S, Ciuleanu TE, Shao J, Bridges K. Am J Hematol; 2010 Sep; 85(9):655-63. PubMed ID: 20661916 [Abstract] [Full Text] [Related]
5. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia. Charu V, Saidman B, Ben-Jacob A, Justice GR, Maniam AS, Tomita D, Rossi G, Rearden T, Glaspy J. Oncologist; 2007 Oct; 12(10):1253-63. PubMed ID: 17962619 [Abstract] [Full Text] [Related]
6. Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks. Vadhan-Raj S, Mirtsching B, Charu V, Terry D, Rossi G, Tomita D, McGuire WP. J Support Oncol; 2003 Oct; 1(2):131-8. PubMed ID: 15352656 [Abstract] [Full Text] [Related]
7. Darbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT). Martelli O, Garassino M, Sacchetta S, Caristo R, Zivi A, Cerbone L, Mancuso A. Anticancer Res; 2008 Oct; 28(3B):1767-71. PubMed ID: 18630457 [Abstract] [Full Text] [Related]
8. Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis. Mirtsching B, Charu V, Vadhan-Raj S, Colowick AB, Rossi G, Tomita D, McGuire WP. Oncology (Williston Park); 2002 Oct; 16(10 Suppl 11):31-6. PubMed ID: 12435171 [Abstract] [Full Text] [Related]
9. Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial. Schwartzberg L, Burkes R, Mirtsching B, Rearden T, Silberstein P, Yee L, Inamoto A, Lillie T. BMC Cancer; 2010 Oct 25; 10():581. PubMed ID: 20973982 [Abstract] [Full Text] [Related]
10. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies. Hesketh PJ, Arena F, Patel D, Austin M, D'Avirro P, Rossi G, Colowick A, Schwartzberg L, Bertoli LF, Cole JT, Demetri G, Dessypris E, Dobbs T, Eisenberg P, Fleischman R, Hall J, Hoffman PC, Laber DA, Leonard J, Lester EP, McCachren S, McMeekin S, Meza L, Miller DS, Nand S, Oliff I, Paroly W, Pawl L, Perez A, Raftopoulos H, Rigas J, Rowland K, Scullin DC, Tezcan H, Waples J, Ward J, Yee LK. Cancer; 2004 Feb 15; 100(4):859-68. PubMed ID: 14770445 [Abstract] [Full Text] [Related]
11. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR). Hertel J, Locay H, Scarlata D, Jackson L, Prathikanti R, Audhya P. Am J Nephrol; 2006 Feb 15; 26(2):149-56. PubMed ID: 16636531 [Abstract] [Full Text] [Related]
12. Assessing symptom burden using the M. D. Anderson symptom inventory in patients with chemotherapy-induced anemia: results of a multicenter, open-label study (SURPASS) of patients treated with darbepoetin-alpha at a dose of 200 microg every 2 weeks. Gabrilove JL, Perez EA, Tomita DK, Rossi G, Cleeland CS. Cancer; 2007 Oct 01; 110(7):1629-40. PubMed ID: 17694552 [Abstract] [Full Text] [Related]
13. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis]. Martínez Castelao A, Reyes A, Valdés F, Otero A, López de Novales E, Pallardó L, Tabernero JM, Hernández Jaras J, Lladós F. Nefrologia; 2003 Oct 01; 23(2):114-24. PubMed ID: 12778875 [Abstract] [Full Text] [Related]
14. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration. Toto RD, Pichette V, Navarro J, Brenner R, Carroll W, Liu W, Roger S. Am J Nephrol; 2004 Oct 01; 24(4):453-60. PubMed ID: 15331889 [Abstract] [Full Text] [Related]
15. A randomized, controlled trial comparing darbepoetin alfa correction/maintenance dosing with weekly dosing for treating chemotherapy-induced anemia. Kotasek D, Canon JL, Mateos MV, Hedenus M, Rossi G, Taylor K. Curr Med Res Opin; 2007 Jun 01; 23(6):1387-401. PubMed ID: 17559735 [Abstract] [Full Text] [Related]
16. Randomized phase 2 dose-finding study of weekly administration of darbepoetin alpha in anemic patients with lung or ovarian cancer receiving multicycle platinum-containing chemotherapy. Ichinose Y, Seto T, Nishiwaki Y, Ohe Y, Yamada Y, Takeda K, Saijo N, Hotta T. Jpn J Clin Oncol; 2010 Jun 01; 40(6):521-9. PubMed ID: 20508073 [Abstract] [Full Text] [Related]
17. Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial. Charu V, Belani CP, Gill AN, Bhatt M, Tomita D, Rossi G, Ben-Jacob A. Oncologist; 2007 Jun 01; 12(6):727-37. PubMed ID: 17602062 [Abstract] [Full Text] [Related]
18. Phase III clinical trials with darbepoetin: implications for clinicians. Glaspy J. Best Pract Res Clin Haematol; 2005 Jun 01; 18(3):407-16. PubMed ID: 15792914 [Abstract] [Full Text] [Related]
19. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients. Mahajan S, Boulton H, Gokal R. J Nephrol; 2004 Jun 01; 17(5):687-92. PubMed ID: 15593036 [Abstract] [Full Text] [Related]
20. Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients. Jadoul M, Vanrenterghem Y, Foret M, Walker R, Gray SJ. Nephrol Dial Transplant; 2004 Apr 01; 19(4):898-903. PubMed ID: 15031347 [Abstract] [Full Text] [Related] Page: [Next] [New Search]